Biow 4 feb

FierceBiotech THE BIOTECH INDUSTRY’S DAILY MONITOR

APTN BioWednesday Queen Mary Innovation Centre, 42 New Road, London E1 2AX

Programme

4 February 2015

16.15

Registration and Refreshments

16.45

Introduction and Welcome from APTN

17.00

Keynote Address: The Ebola Epidemic: An insider’s story Ed Cole, International Advisory Board of Masanga Hospital. Sierra Leone Nicholas Mellor Co-founder of the Masanga MENTOR Ebola Initiative

17.30

Q&A with Ed Cole

18.00

Networking over tea/coffee and biscuits

18.30

Introduction and Welcome from One Nucleus

18.40

Panel Debate Chaired by John Carroll, Editor-in-Chief, FierceBiotech “Biotech financing in the UK”

Panellists: Anja Koenig, Managing Director, Novartis Venture Fund

Patrick Verheyen, Head, J&J Innovation, London Francesco deRubertis, Partner, Index Ventures David Phillips, Partner, SR One 19.30

Closing Remarks

19.40

Networking over drinks

20.00

Close

Profiles Chair Stephen Little

Stephen Little is Chairman of the Asia Pacific Technology Network. He has a PhD from the Royal College of Art, London, has held appointments in Information Systems at universities in Australia and the UK and until 2013 was Senior Lecturer in Knowledge Management at the Open University Business School.

He is a Fellow of the Regional Studies Association and a board member of Asia Pacific Researchers in Organization Studies (APROS). His current research interests include the global migration of skilled labour, the contribution of large science projects to innovation in the wider economy and the role of placebranding and heritage in regional development.

Keynotes Ed Cole

Ed Cole is the MD and Founder of EDAC Intellectual Property Management Consulting services, and, since 2006, has been Chairman of the international Board of Masanga Hospital, Sierra Leone. This provides Executive Board leadership in a pan-European group comprising of physicians and business professionals operating a 100 bed hospital in Sierra Leone (Masanga Hospital www.masangahospital.org.) Led negotiation with the Government of Sierra Leone for rehabilitation and management of the Hospital, which currently provides maternity, paediatric, general health care and have strong education and sustainability business units. It runs a Technology and Health Sciences Training College and a pioneering surgical training program. Under its Masanga Mentor ebola initiative, it is using advanced technology to transform training to combat the spread of ebola http://www.telegraph.co.uk/news/ telegraphchristmasappeal/11308607/How-gaming-technology-could-stop-thespread-of-Ebola.html) Ed holds a PhD in chemistry, and with over 20 years experience in intellectual property (IP) management, technology transfer, patent assertion licensing, innovation scouting and business development in major multinational and SME businesses. (BTG, BT, Rovi).

Nicholas Mellor

Nicholas Mellor has founded a number of start-up businesses, humanitarian ventures, foundations and international organisations, which include Merlin – one of the world’s leading agencies involved in emergency public health programmes, now partnered with Save the Children. Nicholas was the leader of the Lassa Fever Initiative which was set up 10 years ago to build operational and research capacity in West Africa to respond to the challenge of haemorrhagic fevers and emerging pathogens.

His Specialties: These initiatives have ranged from vaccine development (the rDNA Hep B vaccine and later the Children’s Vaccine Initiative), healthcare (Merlin), intellectual property and health research (MIHR – with the support of the Rockefeller Foundation), orphan diseases (hydatid disease and Lassa Fever), the financing of essential medicines, as well as palliative care.

Chair John Carroll

John D. Carroll is a biotech analyst with 32 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications.

He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family

Panel Anja König

Dr. Anja König is a Managing Director in Basel, Switzerland. She is active in the UK, Switzerland and the rest of Europe. Prior to joining Novartis Venture Fund she was an Associate Partner at McKinsey and Company in New York, a global consultancy, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. Anja serves on the boards of Bicycle Therapeutics, F2G, Forendo Pharma and Heptares Therapeutics.

Patrick Verheyen

Patrick is Head of Johnson & Johnson Innovation, London. Prior to this role, Patrick was Vice President, New Ventures within Janssen Pharmaceutical Companies of Johnson & Johnson. In this position, he led a nimble and diverse team that facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow.

Previously, Patrick was Vice President, Mergers & Acquisitions within the Janssen Pharmaceuticals Group. In this role, Patrick facilitated strategic collaborations and acquisitions including Crucell, Elan and Cougar Biotechnology, and established a spin-out company, Movetis, based on Johnson & Johnson’s gastrointestinal pipeline portfolio. Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large cap space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations (CROs), private equity and government institutions.

Patrick joined the Johnson & Johnson Family of Companies in 1985 at Janssen Pharmaceutica N.V. in Beerse, Belgium. In 1996, he relocated to the USA as Director, Business Development, Pharmaceuticals Group, and in 1997, was promoted to Vice President, Corporate Development, Ortho-McNeil Pharmaceutical.

He studied bio-engineering at the University of Leuven, Belgium.

Kevin Johnson, Index Ventures

Kevin is a Partner at Index Ventures working out of the London office. Prior to that he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio.

Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer.

Kevin led both the development of CAT’s platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development. Two of these are now marketed, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK). He was also part of the management team that floated CAT on the London Stock Exchange (main market).

Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.

David Phillips,

David joined SR One in 2008 to pioneer a new function to incubate and spinout technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.

David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London.

Delegate list First name Will Gideon Edward Suleman John Sarah Ruth Nick David Owen Andreas Nigel Toby Saadia Richard Simon Jonathan Romain Amber

Surname Addison Agbanoma Agne Ali Ansell Arbe-Barnes Ashton Ayers Bailey Bain Ballis Banister Basey-Fisher Basharat Bax Bayly Beech Bejot Bielecka

Company Apta Biosciences Ltd Venner Shipley LLP The Communications Strategy Group Inc. Holly IP TranScrip Partners Artemida Pharma Instinctif Partners ( Life Sciences) Sequani Ltd Seraph Partners LLP UCL Imperial Consultants Rare Biotech Ltd Eva Diagnostics Alacrita TranScrip Partners Epiphany Capital The Institute of Cancer Research ImaginAb Consilium Strategic Communications

Elliot Paul Emilie Sophie Simon John Desmond Sapna Ray Iphigenie Louise Michael Mary Helen Ed Nigel Paul Francesco Inga Peter Jessica Mark Alexia Harriet Lawrence Donna Bradley Olav Michele David Nastaran Phil Kevin Tony Priya Pradyp Kieron Jim Dominique anja Andrey Felix Gene Jennifer Anna Thomas

Bland Branthwaite Braun Brayne Bury Carroll Cave Chadha Chan Charatsi Chisholm Chrobak Clark Cohen Cole Crockett Cronin De Rubertis Deakin Dudek Dugan Eccleston Faure Fear Fenelon Hackett Hardiman Hellebo Hill-Perkins Hipkiss Hornett Jackson Johnson Jones Kalia Kanabar Kelly Kinnier Wilson Kleyn koenig Kozlov Kruger Kym Laird Leathley Leonard

Queen Mary Innovation Ltd TranScrip Partners SANOFI IP Pragmatics Limited SYNthesis med chem FierceBiotech BioReliance Inc SCH Global Ltd Bioline Reagents Ltd Public Health England Imperial Consultants Choose New Jersey Hume Brophy HC Pharma Consultancy Limited International Board of Masanga Tukan Partners Ltd Clinical Network Services (CNS) Pty Ltd Index Ventures Imperial Innovations Entrepreneurs Fund Management LLP Poiesis Therapeutics OncoLytika Ltd Hume Brophy One Nucleus Beauchamp Technology Abzena PLC Cambridge Enterprise Limited University of Cambridge Reneuron Group Plc Queen Mary Innovation Ltd Prosonix Ltd Queen Mary BioEnterprises Ltd MedCity Index Ventures One Nucleus Instinctif Partners ( Life Sciences) Bio-Analytical Technologies (UK) Limited Cancer Research Technology Ltd Penningtons Manches LLP Sierra MedTech Ltd Novartis Venture Fund RBV Captital UCL MRC Laboratory of Molecular Biology Eli Lilly and Co. Carpmaels & Ransford LLP Kilburn & Strode LLP

John

Lewis

Londoneast-UK Ltd

Stephen Elena Dave Christine Supriya Niall John Jamie Nicholas Lisa Fiona Ajay Chris Ian Mo Jessica David Jennifer Martyn Phillip Bill Stephen Ajan Ramsay Dave Mitch Ellen

Little Lovo Madge Marquis Mathur McAlister McCafferty McQuade Mellor Melton Middleton Mistry Molloy Nicholson Noonan Paolini Phillips Pierce Postle Price Primrose Reese Reginald Richmond Roberts Rogers Rose

Jutta Clare Felicity Philip Oliver Sahar Nadia Karl Aleksander Magdalena Jonathon William Victoria Tim Alan Natalie Juliet Mark Jonathan

Roth Sansom Sartain Sasson Sexton Shepperd Shivji Simpson Slemensek Sommenvik Spanos Sprigings Stewart Sturgeon Stuttle Thomas Thompson Thompson Tobin

Asia Pacific Technology Network PharmaVentures Ltd WuXI Apptec Inc Londoneast-UK Ltd Hume Brophy Olswang IONTAS Ltd IMS Health Ltd International Board of Masanga Nature Biotechnology Cancer Research Technology Ltd Isogenica Ltd The State University of New Jersey F2G Ltd FTI Consulting Choose New Jersey SR One Ltd Charles Russell Speechlys LLP Cambridge Healthcare and Biotech Ltd Dehns Ithaka Life Sciences Ltd Olswang Cell Therapy Ltd Queen Mary BioEnterprises Ltd Selcia Limited Public Health England Johnson & Johnson Innovation University of Oxford - Medical Sciences Business Development Dr Clare Sansom (freelance) NanoScientium Ltd Sasson Ltd Midven Limited Bristows LLP One Nucleus Liftstream Ltd Advantum Solutions Theradex (Europe) Ltd Cell Therapy Ltd BioPark Abingworth LLP Silence Therapeutics plc The Institute of Cancer Research Clinical Network Services (CNS) Pty Ltd Precision Ocular Sidley Austin LLP Imperial Innovations

Melanie Richard Lisa Patrick Gary Malcolm Will Nina Christopher Helen

Toyne Sewell Turner Urquhart Verheyen Waanders Weir West White Wilkins Wise

Instinctif Partners ( Life Sciences) Clinical Network Services (CNS) Pty Ltd EP Vantage J&J Innovation Zeus Capital Heptares Therapeutics Ltd Cancer Targeting Systems (CTS) Boult Wade Tennant Dehns UCL